BRPI0510817A - protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença - Google Patents

protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença

Info

Publication number
BRPI0510817A
BRPI0510817A BRPI0510817-9A BRPI0510817A BRPI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A
Authority
BR
Brazil
Prior art keywords
protease
disease
treating
pharmaceutical composition
diabetes type
Prior art date
Application number
BRPI0510817-9A
Other languages
English (en)
Inventor
Allan Svendsen
Svend Kaasgaard
Kim Borch
Morten Fischer
Dan Pettersson
Peter Colin Gregory
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of BRPI0510817A publication Critical patent/BRPI0510817A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

PROTEASE, USO DE UMA PROTEASE, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA O TRATAMENTO DE UMA DOENçA O uso farmacêutico de proteases relacionadas a uma protease derivada da Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), opcionalmente em combinação com uma lipase e/ou uma amilase. Os exemplos de indicações médicas são: Tratamento de distúrbios digestivos, insuficiência exócrina pancreática (PEI), pancreatite, fibrose cística, diabete tipo I, e/ou diabete tipo II.
BRPI0510817-9A 2004-05-24 2005-05-24 protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença BRPI0510817A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400810 2004-05-24
DKPA200500101 2005-01-20
PCT/DK2005/000342 WO2005115445A1 (en) 2004-05-24 2005-05-24 Enzymes for pharmaceutical use

Publications (1)

Publication Number Publication Date
BRPI0510817A true BRPI0510817A (pt) 2007-11-20

Family

ID=34968404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510817-9A BRPI0510817A (pt) 2004-05-24 2005-05-24 protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença

Country Status (12)

Country Link
US (2) US20110158976A1 (pt)
EP (1) EP1755656B1 (pt)
JP (1) JP2008500055A (pt)
AT (1) ATE473010T1 (pt)
AU (1) AU2005247061A1 (pt)
BR (1) BRPI0510817A (pt)
CA (1) CA2586222A1 (pt)
DE (1) DE602005022187D1 (pt)
DK (1) DK1755656T3 (pt)
MX (1) MXPA06013239A (pt)
RU (1) RU2389504C2 (pt)
WO (1) WO2005115445A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
ES2358092T3 (es) 2003-10-10 2011-05-05 Novozymes A/S Variantes de proteasa.
MXPA06014649A (es) 2004-06-21 2007-03-12 Novozymes As Proteasas.
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8455235B2 (en) * 2007-12-04 2013-06-04 Novozymes A/S Protease variants for pharmaceutical use
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
ES2378377T3 (es) * 2008-06-03 2012-04-11 Novozymes A/S Método para la producción de un hidrolizado de caseína
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105031628B (zh) * 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
DK2734633T3 (da) 2011-07-22 2019-06-11 Novozymes North America Inc Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2014068083A1 (en) 2012-11-01 2014-05-08 Novozymes A/S Method for removal of dna
EP2910129A1 (de) * 2014-02-21 2015-08-26 Clariant Produkte (Deutschland) GmbH Zusammensetzung für die enzymatische Ölentschleimung
JP6607409B2 (ja) * 2017-03-31 2019-11-20 株式会社東洋新薬 経口用組成物
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK564086A (da) 1986-11-25 1988-06-17 Novo Industri As Enzymatisk detergent-additiv
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
CA2222682A1 (en) * 1995-05-31 1996-12-05 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
FR2747045B1 (fr) * 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
RU2268065C2 (ru) * 1999-03-17 2006-01-20 Зольвай Фармасьютиклз Гмбх Лекарственное средство, предназначенное для лечения диабета
MX261332B (es) * 2000-02-08 2008-10-14 Hoffmann La Roche Uso de proteasas estables en acido para alimento de animales.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
WO2003106667A2 (en) * 2002-06-12 2003-12-24 Bayer Healthcare Ag Regulation of human subtilase-like serine protease
ATE463563T1 (de) 2003-06-19 2010-04-15 Novozymes As Verbesserte proteasen und verfahren zu ihrer herstellung
WO2004111222A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
US7179630B2 (en) 2003-06-19 2007-02-20 Novozymes A/S Thermostable proteases
ES2358092T3 (es) 2003-10-10 2011-05-05 Novozymes A/S Variantes de proteasa.

Also Published As

Publication number Publication date
US20120207741A1 (en) 2012-08-16
ATE473010T1 (de) 2010-07-15
US20110158976A1 (en) 2011-06-30
CA2586222A1 (en) 2005-12-08
WO2005115445A1 (en) 2005-12-08
EP1755656A1 (en) 2007-02-28
DK1755656T3 (da) 2010-10-04
RU2389504C2 (ru) 2010-05-20
AU2005247061A1 (en) 2005-12-08
RU2006145899A (ru) 2008-06-27
EP1755656B1 (en) 2010-07-07
MXPA06013239A (es) 2007-02-28
JP2008500055A (ja) 2008-01-10
DE602005022187D1 (de) 2010-08-19

Similar Documents

Publication Publication Date Title
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
MX2007015471A (es) Amilasas para uso farmaceutico.
NO20080438L (no) Proteaser til farmasoytisk anvendelse
TW200738256A (en) Lipases for pharmaceutical use
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
NO20065195L (no) Terapeutiske enzymformuleringer og anvendelser derav
TW200504078A (en) Therapeutically active compounds and their use
MXPA06014462A (es) Composiciones y metodos para tratamiento de enfermedades cardiovasculares.
NZ623123A (en) A process for concentration of a polypeptide
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
HK1109876A1 (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.